Navigation Links
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
Date:7/11/2014

psy." said Douglas Reynolds, President, Sunovion Pharmaceuticals Canada Inc.."Adequate seizure control remains an unmet medical need for a significant number of patients and Sunovion is committed to providing a treatment option to address this need."

About Partial-Onset Seizures
Epilepsy is a chronic neurological condition characterized by recurrent seizures resulting from abnormal firing of impulses from nerve cells in the brain2. In partial-onset seizures, these bursts of electrical activity are initially focused in specific areas of the brain, but may become more widespread, with symptoms varying according to the affected areas3,4.

About APTIOMTM
APTIOMTM, a voltage-gated sodium channel inhibitor, is a prescription medicine approved for use as adjunctive treatment of partial-onset seizures. Treatment with APTIOMTM should be initiated at 400 mg once daily. After one week, dosage may be increased to the recommended maintenance dosage of 800 mg once daily. Some patients may benefit from the maximum recommended maintenance dosage of 1,200 mg once daily, although this dosage is associated with an increase in adverse reactions. The maximum dose of 1,200 mg daily should only be initiated after the patient has tolerated 800 mg daily for at least a week. For some patients, treatment may be initiated at 800 mg once daily if the need for additional seizure reduction outweighs an increased risk of adverse reactions during initiation.  The initial research and development of eslicarbazepine acetate was performed by BIAL, a privately held Portuguese research-based pharmaceutical company. Subsequently, Sunovion acquired the rights under an exclusive license to further develop and commercialize eslicarbazepine acetate in the U.S. and Canadian markets from BIAL. Eslicarbazepine acetate was approved on November 8, 2013, by the U.S. FDA as adjunctive treatment of partial-
'/>"/>

SOURCE Sunovion Pharmaceuticals Canada Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
2. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
3. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
4. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
5. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
6. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
7. Actinium Pharmaceuticals Announces 2013 Annual Shareholder Meeting
8. Avanir Pharmaceuticals to Participate in Two Conferences in December
9. Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
10. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
11. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (HZDR), the Vienna University of Technology and the ... nearly perfect semiconductor crystals into a silicon nanowire. ... very fast and multi-functional processing units can be ... The research results will be published in the ... considered the cornerstone of future chip technology, but ...
(Date:7/23/2014)... 23, 2014  Having the right people at the ... accelerating business growth and achieving clinical and operational goals. ... Leadership Summit, July 20-22, 2014, in San ... executives and healthcare experts discussing how partnerships have positively ... President & Chief Executive Officer of Cape Regional Medical ...
(Date:7/23/2014)... - BioAmber Inc. (NYSE: BIOA ), ... that the underwriters of its common stock offering ... additional 420,000 shares of common stock at the ... underwriting discounts and commissions, in connection with its ... of common stock, bringing the expected net proceeds ...
(Date:7/23/2014)... -- China Cord Blood Corporation (NYSE: CO ) ("CCBC" ... cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem ... company catering to the mother and child segment, today announced that ... PRC, Singapore , Hong Kong ... the Philippines and Malaysia ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4
... 24 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it will hold a conference call to discuss,the ... update,including an update on the clinical development plan ... Ph.D., chairman and chief,executive officer, Ronald A. Martell, ...
... Ill., July 24 Sagent Pharmaceuticals, Inc.,a privately-held ... ceftazidime for injection, USP, a semisynthetic,broad-spectrum, beta-lactam antibiotic. ... dose vials and 6g pharmacy bulk package vials. ... in the United States were,approximately $45.7 million., ...
... Company reports double-digit sales and earnings growth, ... LLY ) today announced financial results for ... presented on a reported basis. Reported,results were prepared ... include all sales and expenses recognized by the,company ...
Cached Biology Technology:Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31 2Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP 2Lilly Reports Solid Second-Quarter Results 2Lilly Reports Solid Second-Quarter Results 3Lilly Reports Solid Second-Quarter Results 4Lilly Reports Solid Second-Quarter Results 5Lilly Reports Solid Second-Quarter Results 6Lilly Reports Solid Second-Quarter Results 7Lilly Reports Solid Second-Quarter Results 8Lilly Reports Solid Second-Quarter Results 9Lilly Reports Solid Second-Quarter Results 10Lilly Reports Solid Second-Quarter Results 11Lilly Reports Solid Second-Quarter Results 12Lilly Reports Solid Second-Quarter Results 13Lilly Reports Solid Second-Quarter Results 14Lilly Reports Solid Second-Quarter Results 15Lilly Reports Solid Second-Quarter Results 16Lilly Reports Solid Second-Quarter Results 17Lilly Reports Solid Second-Quarter Results 18Lilly Reports Solid Second-Quarter Results 19Lilly Reports Solid Second-Quarter Results 20Lilly Reports Solid Second-Quarter Results 21
(Date:7/23/2014)... Canada has issued a high health risk warning for ... the region due to forest fires. In the ... drifting eastward along normal wind patterns. Fire is ... from fires is not quite so obvious and its ... type of fire (forest, brush, crop, structure, tires, waste ...
(Date:7/23/2014)... DC -- The planet,s soil releases about 60 billion ... is far more than that released by burning fossil ... This enormous release of carbon is balanced by carbon ... other plant matter, as well as by the underground ... have documented that rising temperatures increase the rate of ...
(Date:7/23/2014)... local and national governments struggle to deal with ever-growing ... refining the picture of just how much there is ... ACS journal Environmental Science & Technology , their ... developed countries discard floods into just seven developing countries ... who live there. , Knut Breivik and colleagues note ...
Breaking Biology News(10 mins):Climate change and the soil 2
... State University have solved a long-standing conundrum about ... way into limestone, sand grains, mussel shells, coral ... According to the lead investigator, ASU professor ... what is "at the heart of an erosive ...
... sugar may be enough to cool a hot temper, at least ... found that people who drank a glass of lemonade sweetened with ... than did people who consumed lemonade with a sugar substitute. ... simple sugar found in the bloodstream that provides energy for the ...
... 30, 2010Access to quality reproductive healthcare for women around ... human rights, freedom, equity, and right to control her ... Health in the current issue of Journal of Women,s ... Inc., explores the compelling medical, socioeconomic, and gender-based factors ...
Cached Biology News:Mystery dissolves with calcium pump discovery 2Mystery dissolves with calcium pump discovery 3Researchers find link between sugar, diabetes and aggression 2Researchers find link between sugar, diabetes and aggression 3Researchers find link between sugar, diabetes and aggression 4Ensuring the rights of women worldwide to reproductive health care 2
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
...
Biology Products: